Oncomine™ Dx Express™ Test for Non–Small Cell Lung Cancer (NSCLC) Treatment Monitoring
The Oncomine Dx Express Test is an FDA-approved, fully automated next-generation sequencing (NGS) assay performed on the Ion Torrent Genexus Dx Integrated Sequencer. It delivers both companion diagnostic (CDx) results for EGFR exon 20 insertion mutations in NSCLC (for treatment with ZEGFROVY® (sunvozertinib) and broader tumor profiling biomarkers recommended by professional guidelines for multiple solid tumors. This includes substitutions, insertions, and deletions in 42 genes, copy number variants in 10 genes, and fusion or splice variants in 18 genes relevant in NSCLC, colorectal cancer, cholangiocarcinoma, and melanoma, among others.
- Companion diagnostic for NSCLC patients with EGFR exon 20 insertion mutations eligible for ZEGFROVY® (sunvozertinib)
- Aid in therapy treatment and monitoring for NSCLC and other cancer such colorectal cancer, cholangiocarcinoma, and melanoma
No pathogenic variants (mutations) detected
Formalin fixed paraffin embedded (FFPE) tissue samples.
Stability
FFPE samples are stable at room temperature for longer.
- JMA J. 2024 Jul 16;7(3):375-386. [PMID: 39114611]
- Genes (Basel). 2023 Jun 2;14(6):1219. [PMID: 37372399]
- Clin Lung Cancer. 2019; 20: 20-29.e8. [PMID: 30243889]
- Cancers (Basel). 2019;11. pii: E1309. [PMID: 31491926]
- Adv Exp Med Biol. 2016; 893: 1-19. [PMID: 26667336]
- N Engl J Med. 2014 Nov 20;371(21):1963-71. [PMID: 25264305]
- Thorac Cancer. 2021 Feb;12(4):504-511. [PMID: 33350072]
- Oncomine® Dx Target Test User Guide, Rev C.0, 2017
- Thermo Fisher Scientific: Oncomine Dx Express Test